
|Videos|December 1, 2017
Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).
Advertisement
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).
Given the data seen in the metastatic space, the field is moving toward immunotherapy-based approaches, says Voss. This is especially true for preoperative trials in non-metastatic disease.
The phase III PROSPER RCC trial (NCT03055013) is comparing nephrectomy with or without nivolumab (Opdivo), and is currently accruing in the United States.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5


































